The reverse merger with Nasdaq-listed Mirna, which counts Pfizer and Baxter as backers, was agreed alongside the disclosure of a $42m series C round.
US-based biopharmaceutical company Synlogic agreed a reverse merger with Nasdaq-listed biopharmaceutical firm Mirna Therapeutics on Tuesday through an all-stock transaction.
The deal will be conducted through a wholly-owned, undisclosed subsidiary of Mirna. The merged company will operate under the Synlogic name and Synlogic’s shareholders will own approximately 83% of the combined entity.
Jose Carlos Gutierrez-Ramos, chief executive of Synlogic, will remain in the same position for the merged company, which will be listed on the Nasdaq stock exchange under a…
